In a nutshell This study aimed to investigate the safety and effectiveness of the combination of all-trans-retinoic acid (Vesanoid), arsenic trioxide (Trisenox), and idarubicin (Idamycin) as front-line treatment for acute promyelocytic leukemia. This study concluded that this combination is safe and effective for these...
Read More
In a nutshell This study aimed to compare the safety and effectiveness of bendamustine–rituximab (BR) and chlorambucil–rituximab (Chl-R) as a front-line treatment in older patients with chronic lymphocytic leukemia (CLL). This study concluded that both treatments are good options for these...
Read More
In a nutshell This study aimed to investigate the impact of time to response to treatment on the outcomes of patients with accelerated-phase chronic myeloid leukemia. This study concluded that an early response to treatment is strongly associated with long-term survival in these patients. Some background Tyrosine...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of combining daunorubicin (Cerubidine) and cytarabine (Cytosar-U) compared to idarubicin (Idamycin) and cytarabine as induction treatment for patients with acute myeloid leukemia. This study concluded that the idarubicin and cytarabine combination...
Read More
In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...
Read More
In a nutshell This study aimed to compare two salvage regimes for patients with relapsed/refractory acute myeloid leukemia. This study concluded that both regimens have similar effectiveness in terms of overall response but one shows a significant reduction in side effects in these patients. Some background...
Read More
In a nutshell This study aimed to investigate the occurrence of atrial fibrillation (abnormal heart rhythm) in patients with chronic lymphocytic leukemia who are treated with ibrutinib. This study concluded that atrial fibrillation does not require ibrutinib treatment to be stopped but is associated with worse outcomes for...
Read More
In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia. This study concluded that this treatment combination is safe and effective as a salvage treatment...
Read More
In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....
Read More
In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was safe and effective as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia. This study concluded that acalabrutinib was safe and effective in these patients. Some background Acalabrutinib is commonly...
Read More
In a nutshell This review aimed to discuss the toxicities of ibrutinib (Imbruvica) treatment and how to manage them. This review concluded that patients should be regularly monitored for toxicities and actively treated to reduce side effects and avoid disruption to treatment. Some background Ibrutinib is a...
Read More
In a nutshell This study aimed to compare the effectiveness and safety of generic and branded imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. This study concluded that generic and branded imatinib had similar effectiveness and safety in these patients. Some...
Read More
